Strategic approaches for colon targeted drug delivery: an overview of recent advancements
Open accessAbstract
Colon targeted drug delivery systems have gained a great deal of attention as potential carriers for the local treatment of colonic diseases with reduced systemic side effects and also for the enhanced oral delivery of various therapeutics vulnerable to acidic and enzymatic degradation in the upper gastrointestinal tract. In recent years, the global pharmaceutical market for biologics has grown, and increasing demand for a more patient-friendly drug administration system highlights the importance of colonic drug delivery as a noninvasive delivery approach for macromolecules. Colon-targeted drug delivery systems for macromolecules can provide therapeutic benefits including better patient compliance (because they are pain-free and can be self-administered) and lower costs. Therefore, to achieve more efficient colonic drug delivery for local or systemic drug effects, various strategies have been explored including pH-dependent systems, enzyme-triggered systems, receptor-mediated systems, and magnetically-driven systems. In this review, recent advancements in various approaches for designing colon targeted drug delivery systems and their pharmaceutical applications are covered with a particular emphasis on formulation technologies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Colonic drug delivery is beneficial for treating arthritis, angina, nocturnal asthma, and colonic disorders such as colorectal cancer, Crohn's disease, and ulcerative colitis.
“Colonic drug delivery is beneficial for treating arthritis, angina, nocturnal asthma, and colonic disorders such as colorectal cancer, Crohn’s disease, and ulcerative colitis (Arévalo-Pérez et al., 2020; Lee et al., 2020; Naeem et al., 2020; Cui et al., 2021).”
From pH stimuli-responsive hydrogels from non-cellulosic biopolymers for drug delivery. (2023) · cites this paper as Lee et al., 2020
The Summary supports benefits for local treatment of inflammatory bowel disease and colorectal cancer, and the pH-dependent delivery section discusses delivery in Crohn’s patients. The passages do not support the claimed benefits for arthritis, angina, or nocturnal asthma. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 114 · Cited by 318
- Authors
- Lee, S. H., Bajracharya, R., Min, J. Y., Han, J.-W., Park, B. J., & Han, H.-K.
- Affiliations
- Dongguk University (KR)
- College of Pharmacy, Dongguk University-Seoul, Dongguk-ro 32, Ilsan-Donggu, Goyang 10326, Korea
- Corresponding author
- Han, Hyo-Kyung
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-01-15
- Volume
- 12
- Issue
- 1
- Pages
- 68
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7022598
- OpenAlex
- W3000072346
- Cited by
- 318
- References
- 114
- Citations by year
- 2026: 44 · 2025: 58 · 2024: 56 · 2023: 49 · 2022: 50 · 2021: 36 · 2020: 24 · 2018: 1
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation (2018R1A5A2023127)
- National Research Foundation of Korea (2018R1A5A2023127, No. 2019R1A2C2004873 and No. 2018R1A5A2023127, 2019R1A2C2004873)
- Ministry of Science and ICT, South Korea (2018R1A5A2023127)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- colon-targeted drug delivery, oral drug delivery, pH-responsive drug delivery, enzyme-responsive drug release, receptor-mediated drug delivery, magnetic drug delivery, macromolecule delivery, colonic diseases, drug formulation technology, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
